Danaher reports earnings, revenue increases in Q2

By The Science Advisory Board staff writers

July 23, 2021 -- Danaher announced earnings and revenue increases for its second quarter of 2021 (end-July 2).

Danaher said that revenues increased 36.5% year-over-year to $7.2 billion, while net earnings were $1.7 billion, an 84% year-over-year increase from the 2020 period.

Rainer Blair, company president and CEO, said broad-based strength across the portfolio helped the company deliver on core revenue growth, as well as growth in earnings per share and cash flow generation.

Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as...
Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines.
Danaher announces chief executive transition
Danaher announced on May 6 that Executive Vice President Rainer Blair will succeed Thomas Joyce Jr. as president and CEO when Joyce retires on September...

Copyright © 2021 scienceboard.net

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter